Medication info
Valsartan Film-Coated Tablet 160 mg (Valsartan)

Valsartan Film-Coated Tablet 160 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tablet
Manufacturer / importer
DongKwang Pharmaceutical Co., Ltd.
Appearance
Orange-yellow oblong film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200805428 · Notified 2008.05.13 · Insurance code 645903690

Summary

Main use
Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; improvement of heart failure
Who takes it
Adults · Children
Adult dose
* 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended to take this medication at the same time each day (e.g., in the morning), if possible. 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this medication once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medication once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medication once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medication once daily and do not exceed 80 mg daily. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medication orally twice daily, which may be increased to 80 mg or 160 mg per dose. If a diuretic is coadministered, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medication, an ACE inhibitor, and a beta blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medication twice daily; over the following weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or greater. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medication. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, it is preferable not to exceed a daily dose of 80 mg. If administering more than 80 mg daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
DongKwang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; improvement of heart failure

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This medication is used to lower and control blood pressure in patients with essential hypertension. It also helps improve symptoms in heart failure patients who cannot use ACE inhibitors, particularly those in NYHA class II–IV. After myocardial infarction, it contributes to improved survival by reducing the risk of death in patients with impaired left ventricular function. Thus, it is effective for various heart-related conditions ranging from essential hypertension to heart failure and post-myocardial infarction management. It is used to enhance blood pressure and cardiac function tailored to the patient's condition.

How to take

Adult dose

* 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended to take this medication at the same time each day (e.g., in the morning), if possible. 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this medication once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medication once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medication. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medication once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medication once daily and do not exceed 80 mg daily. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medication orally twice daily, which may be increased to 80 mg or 160 mg per dose. If a diuretic is coadministered, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medication, an ACE inhibitor, and a beta blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medication twice daily; over the following weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medication may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or greater. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medication. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, it is preferable not to exceed a daily dose of 80 mg. If administering more than 80 mg daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medication to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus when taken during pregnancy, particularly in the second and third trimesters. If pregnancy is confirmed, discontinue use immediately. Women who are pregnant or may become pregnant, and breastfeeding women should not take this medication. Patients with severe liver dysfunction, cirrhosis, or biliary obstruction should avoid using this medication. Patients with hereditary angioedema or a history of angioedema should not use this medication. Patients with severely impaired kidney function, primary hyperaldosteronism, or certain kidney disorders associated with diabetes should not take this medication. Elderly patients, those with hyperkalemia, mild liver dysfunction, heart valve disease, or cardiovascular diseases should use this medication with caution. Patients with heart failure or after myocardial infarction should use this medication while closely observing changes in kidney function. This medication lowers blood pressure, and when taken for the first time, may cause a rapid drop in blood pressure leading to dizziness or fainting, so caution is needed. Patients undergoing hemodialysis or on strict sodium restriction, and those taking diuretics may be at risk for hypotension and should start at a low dose while closely monitoring their condition. This medication contains specific dye components, so patients with allergies to them should be cautious. Due to the risk of hyperkalemia, when combined with potassium-sparing diuretics or potassium supplements, blood potassium levels should be closely monitored. Taking this medication concurrently with non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the blood pressure-lowering effect and increase the risk of kidney dysfunction, so caution is advised. When taken with lithium preparations, lithium levels may increase, necessitating monitoring of blood lithium levels. This medication does not significantly affect the CYP450 enzyme system, hence the risk of metabolic interactions with other drugs is low, though interactions related to certain drug transporters in the liver may occur. Safety and efficacy in children and adolescents under 18 years of age have not been established. In case of overdose, severe hypotension, decreased consciousness, or shock may occur, and immediate medical treatment is required. Store this medication out of reach of children and avoid transferring it to other containers. Caution is necessary when driving or operating machinery, as symptoms such as dizziness may occur.

Side effects

  • Headache
  • dizziness
  • viral infection
  • upper respiratory tract infection
  • cough
  • diarrhea
  • fatigue
  • rhinitis
  • sinusitis
  • abdominal pain
Show 50 more
  • stomachache
  • nausea
  • pharyngitis
  • arthralgia
  • hypotension
  • orthostatic dizziness
  • orthostatic hypotension
  • renal function impairment
  • hyperkalemia
  • angioedema
  • heart failure
  • vascular edema
  • erythema
  • itching
  • serum sickness
  • vasculitis
  • syncope
  • epistaxis
  • hepatitis
  • arrhythmia
  • intestinal vascular edema
  • interstitial pneumonia
  • hypoglycemia
  • shock
  • loss of consciousness
  • rhabdomyolysis
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • vesicular dermatitis
  • dyspepsia
  • anemia
  • tinnitus
  • tension headache
  • decreased motor function
  • confusion
  • chest pain
  • rash
  • myalgia
  • edema
  • weakness
  • insomnia
  • decreased libido
  • malaise
  • drowsiness
  • atrial fibrillation
  • vomiting
  • constipation
  • thirst
  • loss of appetite

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is also important to store it in a cool place below 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Orange-yellow oblong film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.